[A19-09] Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2019
Commission awarded on 24.01.2019 by the Federal Joint Committee (G-BA).
Adults with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease
Clear advantages in symptomatic progression, disadvantages in some side effects; indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-36||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-20||Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A19-51||Apalutamide (prostate cancer) - Addendum to Commission A19-09||Commission completed|